Login to Your Account

Tau research's fresh (in)carnation

Although Jefferies analyst Michael Yee noted that the "market is somewhat skeptical" of neurodegenerative disease research at the moment, Prothena Corp. plc CEO Gene Kinney told BioWorld that he expects there will be more, not fewer, of the deals like the potential $2.2 billion pact that his firm struck with Celgene Corp. 

more »

Our Habitat for All Things Science
GWAS in Chinese population implicates immune system in Alzheimer's disease

A study has identified common genetic variants in the Chinese population contributing to the risk of developing Alzheimer's disease (AD) that possibly exert functional effects through the immune system, which could have important implications for AD management.

The search continues for promising biomarkers and effective disease-modifying therapies for AD. The current drug development approaches mainly target the disease's hallmark pathology of amyloid-beta (Abeta) protein accumulation in the brain leading to Abeta plaque deposition.



Partners in Focus